Industry
Researchers
Clinicians
Patients & Families
Advocacy Groups
PrOSPeCT
Our Programs
- - - PROGRAMS
    - Cancer Screening Program (CaSP)
    - Bringing comprehensive genomic profiling to patients with advanced and incurable cancer
    - Molecular Screening and Therapeutics (MoST) study
    - Using the power of genomic technology to characterise molecular changes in a patient's cancer
    - Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
    - Investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer
    - Genetic Cancer Risk in the Young (RisC) study – Now closed
    - Understanding the genetic variants that contribute to inherited cancer
  - - CLINICAL TRIALS
    - Company Studies (C3)
    - Companion Studies (C2)
    - MoST Core Studies (C1)
    - MoST-LLy
    - ASPiRATION
Resources & Events
About Us
News
Contact

Partner Toolkits
Resources & Events
About Us
News
Contact

Sign up for newsletter

Australian Rare Cancer Portal

edit

By Leah Wishart • 28 December 2022

comments

comments for this post are closed

Privacy Policy
Omico is registered not-for-profit company
Site Map
Sign Up for Newsletter